Scholar Rock Holding Corporation (SRRK) Stock

Scholar Rock Holding Corporation (SRRK) is a Healthcare stock trading at $55.20 (as of 2026-08-20), with a market capitalization of $6.61B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Scholar Rock Holding Corporation is a biopharmaceutical company developing therapies that target protein growth-factor signaling. Its programs include apitegromab for spinal muscular atrophy (Phase 3) and SRK-181 for certain cancers resistant to checkpoint inhibitor antibodies (Phase 1), alongside a pipeline spanning neuromuscular disorders, cancer, and fibrosis, including collaboration with Gilead Sciences on inhibitors of TGF-beta activation.

Valuation — source: SEC EDGAR (first-party)

Price	$55.20
Market Cap	$6.61B
Price / Book	23.96
FCF Yield	-8.2%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)

$0.00

Financial Health — source: SEC EDGAR

Altman Z-Score

17.30 (safe)

Valuation vs Sector & Industry

Sector P/E (Healthcare)	21.6
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	FMR LLC ($847.67M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	David L. Hallal
Employees	128
Country	US
IPO Date	2018-05-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Kymera Therapeutics, Inc. (KYMR)
• Krystal Biotech, Inc. (KRYS)
• Immunovant, Inc. (IMVT)
• Vaxcyte, Inc. (PCVX)
• Twist Bioscience Corporation (TWST)
• ImmunityBio, Inc. (IBRX)
• CG Oncology, Inc. Common stock (CGON)
• Adaptive Biotechnologies Corporation (ADPT)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.